Health Canada authorized an adapted version of the Moderna Spikevax COVID-19 vaccine that targets the Omicron BA.4/BA.5 subvariants. It is authorized for use as a booster dose in individuals 18 years of age or older.
After a thorough and independent scientific review of the evidence, Health Canada has determined that the bivalent Moderna Spikevax booster is safe and effective. Clinical trial results showed that a booster dose of the bivalent Moderna Spikevax vaccine triggers a strong immune response against both Omicron (BA.4/BA.5) and the original SARS-CoV-2 virus strains.
This adapted vaccine has a similar safety profile to the previously approved Moderna Spikevax boosters, with the same mild adverse reactions that resolved quickly.